Drug intelligence / Profile preview

SUVN-L1101142

Development stage: Preclinical
Lead developer: Suven Life Sciences
Modality: Small Molecules

Overview

SUVN-L1101142 is a potent, selective, small-molecule positive allosteric modulator (PAM) of the muscarinic acetylcholine receptor M4 (CHRM4) developed by Suven Life Sciences. It is being investigated for the treatment of psychosis-related disorders and conditions, including schizophrenia and Alzheimer's disease. By targeting the allosteric site of the M4 receptor, SUVN-L1101142 modulates striatal dopamine signaling to alleviate psychotic symptoms while offering a favorable safety profile with a low propensity for motor side effects. Preclinical studies in animal models have demonstrated its efficacy in attenuating amphetamine-evoked hyperlocomotion, prepulse inhibition deficits, and DOI-induced head twitch, as well as reversing time delay-induced memory deficits.

Other names: SUVN-l1101142SUVN-l-1101142SUVN-l 1101142

Targets

CHRM4 (M4)

Beyond the preview

Go deeper on SUVN-L1101142.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUVN-L1101142.